A review of ramelteon in the treatment of sleep disorders.

Article Details

Citation

Copy to clipboard

Neubauer DN

A review of ramelteon in the treatment of sleep disorders.

Neuropsychiatr Dis Treat. 2008 Feb;4(1):69-79.

PubMed ID

18728808 [ View in PubMed

]

Abstract

Ramelteon is a selective melatonin receptor (MT(1) and MT(2)) agonist that has been approved by the US Food and Drug Administration for the treatment of insomnia characterized by difficulty with sleep onset. It is the only approved sleep-promoting medication that does not have a direct sedating effect, but rather enhances sleep through effects on sleep regulatory mechanisms within the suprachiasmatic nucleus. Ramelteon has been shown to have no abuse liability and therefore is not scheduled by the U.S. Drug Enforcement Agency as a controlled substance. It is available as an 8 mg tablet, which should be taken approximately 30 minutes prior to bedtime. The FDA approval contains no limitation on how long the medication may be prescribed.

DrugBank Data that Cites this Article

Drug Enzymes

Drug	Enzyme	Kind	Organism	Pharmacological Action	Actions
Ramelteon	Cytochrome P450 1A2	Protein	Humans	Unknown	Substrate	Details

Drug Interactions

• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental
• All Drugs

Drugs	Interaction
Integrate drug-drug interactions in your software
Ramelteon Fluvoxamine	The serum concentration of Ramelteon can be increased when it is combined with Fluvoxamine.
Ramelteon Enoxacin	The serum concentration of Ramelteon can be increased when it is combined with Enoxacin.
Ramelteon Rofecoxib	The serum concentration of Ramelteon can be increased when it is combined with Rofecoxib.
Ramelteon Ciprofloxacin	The serum concentration of Ramelteon can be increased when it is combined with Ciprofloxacin.
Ramelteon Quinidine	The serum concentration of Ramelteon can be increased when it is combined with Quinidine.